Zhaoke Ophthalmology Limited (6622.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
294
First IPO Date
April 29, 2021
| Name | Title | Pay | Year Born |
| Xiaoyi Li | Chief Executive Officer & Executive Chairman of the Board | 12.61M | 1963 |
| Xiangrong Dai | Chief Operating Officer & Executive Director | 2.23M | 1980 |
| Jiang Feng | Senior Vice President of Sales & Marketing | 0 | 1976 |
| Lit Fui Lau | President & Chief Scientific Officer | 0 | 1963 |
| Yang Lei | Group General Counsel | 0 | 1981 |
| Carol Liu | Group Head of Regulatory Affairs | 0 | 1984 |
| Guohui Zhang | Senior Vice President of Manufacturing & Logistics | 0 | 1974 |
| Suk Yan Yau | Vice President of Financial Dept. & Company Secretary | 0 | 1982 |
| Mauro Bove | Senior Vice President of Corporate Development | 0 | 1955 |
Zhaoke Ophthalmology Limited is an ophthalmic pharmaceutical company dedicated to researching, developing, and commercializing therapeutic solutions addressing significant unmet medical requirements in the People's Republic of China. The company is advancing a range of medications designed for various ocular conditions, impacting both the anterior and posterior segments of the eye, such as dry eye disease, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. It was previously known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was established in 2017 and operates from its headquarters in Guangzhou, People's Republic of China.